RLAY – relay therapeutics, inc. (US:NASDAQ)
Stock Stats
News
Relay Therapeutics (NASDAQ:RLAY) had its "sell (d-)" rating reaffirmed by analysts at Weiss Ratings.
Relay Therapeutics (RLAY): Revisiting Valuation After a Sharp Rebound in 2024 [Yahoo! Finance]
Will Broad Zovegalisib Breast Cancer Data Reshape Relay Therapeutics' (RLAY) Targeted Oncology Narrative? [Yahoo! Finance]
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025 [Yahoo! Finance]
Relay Therapeutics Announces Efficacy Subset Analysis of Zovegalisib (RLY-2608) + Fulvestrant in Breast Cancer Patients Pre-Treated with SERD or with ESR1 Mutations at SABCS 2025
Form 4 Relay Therapeutics, Inc. For: Jan 13 Filed by: Bergstrom Donald A
Form 4 Relay Therapeutics, Inc. For: Jan 13 Filed by: Rahmer Peter
Form 4 Relay Therapeutics, Inc. For: Jan 13 Filed by: Catinazzo Thomas
Form 4 Relay Therapeutics, Inc. For: Jan 13 Filed by: Patel Sanjiv
Form 4 Relay Therapeutics, Inc. For: Jan 06 Filed by: Patel Sanjiv
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.